Could Gum Chewing Aid Motility After Abdominal Cancer Surgery?

Article

Gum chewing might help patients avoid prolonged intestinal motility dysfunction following abdominal cancer surgery, suggested findings reported at the ONS Congress.

Image © Andreas Berheide / Shutterstock.com

Gum chewing might help patients avoid prolonged intestinal motility dysfunction following abdominal cancer surgery, suggested findings reported at the Oncology Nursing Society (ONS) 42nd Annual Congress, held May 4–7 in Denver.

“Simple gum chewing may prevent prolonged postoperative ileus and nurses play a vital role in implementing this intervention,” said lead study author Linda Chan, BSN, RN, OCN, of the University of Texas Southwestern Medical Center in Dallas.

Postoperative ileus affects up to 32% of patients, costing up to $15,000 per episode-more than $750 million a year in the United States, all told. “It also causes immeasurable pain and suffering,” said Chan.

Postoperative ileus has an initial neurologic phase and a subsequent macrophage-mediated inflammatory phase. Chewing stimulates the vagus nerve and gut motility and sweetening agents in sugar-free gum appear to cause an “osmotic effect in the gut” that facilitates intestinal motility, she said.

To assess whether gum chewing affects the risk of postoperative ileus, the research team provided 159 patients who had undergone abdominal cancer surgery with information packets on the potential benefits of gum chewing after surgery and invited them to participate in the study. Patients who were disoriented and could not offer informed consent were excluded from the study. Those patients who opted to participate were given an instruction packets and a supply of their choice of regular or sugar-free gum. The patients were instructed to chew gum 6 hours after surgery or when feeling fully awake, and then four times a day and as desired during recovery. Nurses continued to offer patients gum until their first bowel movements after surgery.

“Bedside nurses are ideally positioned to teach and encourage recovering patients to chew gum,” Chan said.

Ten of 85 patients (11.8%) who abstained from gum chewing and five of 74 patients (6.8%) who participated in the gum-chew intervention experienced postoperative ileus as determined in radiographic imaging reports.

A computerized flowsheet was designed to document gum chewing in patients’ electronic health records.

Gum chewing represents a “low-cost intervention with little risk for alert, oriented, recovering abdominal surgical oncology patients who can safely chew and swallow,” she and her colleagues reported.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content